ACR 2021: New Data on axSpA and axPsA Treatment Options and Health Disparities in Patients With Axial Disease
  • CME

November 3-9, 2021; Virtual Meeting
Get my take on key studies from ACR 2021 on axSpA and axPsA treatment options and health disparities in patients with axial disease.
Atul Deodhar, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: December 22, 2021 Expiration: December 21, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize the latest research findings from ACR 2021 related to axSpA and axPsA management
  • Translate key findings from recent investigations into practical applications in the management of patients with axSpA and axPsA
  • Incorporate key findings and strategies regarding health disparities to reduce disparities and improve outcomes in patients with axial disease

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Atul Deodhar, MD
Professor of Medicine
Medical Director
, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon
Atul Deodhar, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Aurinia, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Lilly, MoonLake Immunotherapeutics, Novartis, Pfizer, and UCB and funds for research support from AbbVie, GlaxoSmithKline, Lilly, Novartis, Pfizer, and UCB.


Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Courtney Duval, PharmD, BCACP
Scientific Director
Courtney Duval, PharmD, BCACP, has no relevant conflicts of interest to report.
Elaine P. Seeskin

Editorial Contributor

Elaine Seeskin has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for dermatology, rheumatology and pediatric physicians, and other healthcare professionals who manage patients with psoriatic disease


The goal of this educational program is to increase the knowledge and competence of learners in evaluating the latest data for axSpA and axPsA from ACR 2021 and integrating the most clinically important data to clinical practice for appropriate management of each condition.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 22, 2021, through December 21, 2022:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.


Supported by an educational grant from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Clinical Care Options (CCO) presents expert faculty discussing options for the treatment and care of patients with rheumatic disease during flu season.

Cassandra Calabrese, DO Released: December 2, 2022

Nurse Practitioners: 0.5 AANP contact hours Released: August 5, 2022 Expired: August 31, 2023

Slides featuring expert discussion of managing the physical and emotional elements of pediatric psoriasis

Victoria Garcia-Albea, NP, DCNP Robert Sidbury, MD, MPH Released: February 8, 2022

Interactive video roundtable featuring expert discussion of managing the physical and emotional elements of pediatric psoriasis.

Victoria Garcia-Albea, NP, DCNP Robert Sidbury, MD, MPH Physicians: maximum of 0.75 AMA PRA Category 1 Credits Nurse Practitioners: 0.75 NAPNAP CE contact hour, 0.25 pharmacology content Released: February 7, 2022 Expired: February 6, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings